Literature DB >> 19381845

Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer.

Attila Tordai1, Cornelia Liedtke, Lajos Pusztai.   

Abstract

Gene expression profiling using DNA microarrays allows simultaneous measurement of thousands of mRNA transcripts in a single experiment. Results from gene expression profiling studies have fundamentally altered our view of breast cancer, which is no longer regarded as a single disease but as several molecularly and biologically distinct neoplastic diseases. This technology has also yielded novel diagnostic assays that have started to have an impact on clinical care. This is a rapidly evolving field, and the constraints of space do not allow us to discuss many of the published studies. Therefore, in this review, we will summarize the results of those gene expression studies that are conceptually and practically most important and discuss some of the limitations and the future promise of this technology.

Entities:  

Mesh：

Year:  2009        PMID： 19381845     DOI： 10.1007/s10585-009-9261-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN： 0262-0898            Impact factor:   5.150


  15 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Authors:  Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

3.  Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.

Authors:  P M Ravdin; I A Siminoff; J A Harvey
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

4.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

5.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

Authors:  Kenneth R Hess; Keith Anderson; W Fraser Symmans; Vicente Valero; Nuhad Ibrahim; Jaime A Mejia; Daniel Booser; Richard L Theriault; Aman U Buzdar; Peter J Dempsey; Roman Rouzier; Nour Sneige; Jeffrey S Ross; Tatiana Vidaurre; Henry L Gómez; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

6.  Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

Authors:  Brian Z Ring; Robert S Seitz; Rod Beck; William J Shasteen; Shannon M Tarr; Maggie C U Cheang; Brian J Yoder; G Thomas Budd; Torsten O Nielsen; David G Hicks; Noel C Estopinal; Douglas T Ross
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

7.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Authors:  Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

8.  Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Authors:  Yun Gong; Kai Yan; Feng Lin; Keith Anderson; Christos Sotiriou; Fabrice Andre; Frankie A Holmes; Vicente Valero; Daniel Booser; John E Pippen; Svetislava Vukelja; Henry Gomez; Jaime Mejia; Luis J Barajas; Kenneth R Hess; Nour Sneige; Gabriel N Hortobagyi; Lajos Pusztai; W Fraser Symmans
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

9.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Authors:  Marc Buyse; Sherene Loi; Laura van't Veer; Giuseppe Viale; Mauro Delorenzi; Annuska M Glas; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian Harris; Jan Bogaerts; Patrick Therasse; Arno Floore; Mohamed Amakrane; Fanny Piette; Emiel Rutgers; Christos Sotiriou; Fatima Cardoso; Martine J Piccart
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

10.  A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

Authors:  Laurel A Habel; Steven Shak; Marlena K Jacobs; Angela Capra; Claire Alexander; Mylan Pho; Joffre Baker; Michael Walker; Drew Watson; James Hackett; Noelle T Blick; Deborah Greenberg; Louis Fehrenbacher; Bryan Langholz; Charles P Quesenberry
Journal:  Breast Cancer Res       Date:  2006-05-31       Impact factor: 6.466
View more
  1 in total

Review 1.  'Omic approaches to preventing or managing metastatic breast cancer.

Authors:  Obi L Griffith; Joe W Gray
Journal:  Breast Cancer Res       Date:  2011-12-08       Impact factor: 6.466
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.